Genzyme Corporation has completed the deal that gives it the rights to the drug worldwide. Multiple Sclerosis Alemtuzumab treatment is no doubt important to the millions of patients suffering for MS around the world. But in the pharmaceutical world successful MS Alemtuzumab trials also is of substantial financial interest to Genzyme Corp. as well. They have secured the rights to commercialize any successful results from Bayer HealthCare. Under the agreement’s terms, Genzyme is making no payments to Bayer upfront, but will make payments in the future to Bayer based on revenue that Multiple Sclerosis Alemtuzumab therapy may generate. It could be a very important revenue generator if the drug is approved and successfully marketed worldwide.
Alemtuzumab is in phase 3 trials and is targeting RRMS, or relapsing-remitting Multiple Sclerosis Alemtuzumab treatment in two separate trials. Bayer will continue to help fund development until the drug is finally approved.
